-
1.发明授权Anti-cMet antibody and its use for the detection and the diagnosis of cancer 有权抗cMet抗体及其用于检测和诊断癌症的用途公开(公告)号：US08673302B2
公开(公告)日：2014-03-18
申请号：US13391435
申请日：2010-08-23
IPC分类号： A61K38/00
CPC分类号： G01N33/57496 , C07K16/2863 , C07K2317/56 , C07K2317/565
摘要： The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to antibodies capable of binding to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding processes, for detecting and diagnosing pathological hyperproliterative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the overexpression of cMet. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers.
摘要翻译： 本发明涉及患者中增殖性疾病的预后和/或诊断领域。 更具体地，本发明涉及能够结合人cMet受体的抗体以及编码这些抗体的氨基酸和核酸序列。 本发明同样包括使用所述抗体和相应的方法来检测和诊断与cMet表达相关的病理性过度压抑性致癌性疾病。 在某些实施方案中，所述疾病是与cMet多肽相对于与cMet的过表达相关的正常或任何其它病理学增加的表达增加相关的致癌性疾病。 本发明最终包括产品和/或组合物或试剂盒，其至少包含用于某些癌症的预后或诊断的抗体。
-
2.发明申请METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST A RESISTANCE ANTIGEN, ANTIBODIES OBTAINED BY SAID METHOD AND THEIR USES 有权用于产生抗性抗原的活性抗体的方法，通过方法获得的抗体及其用途公开(公告)号：US20130028835A1
公开(公告)日：2013-01-31
申请号：US13544672
申请日：2012-07-09
IPC分类号： A61K39/395 , A61K39/00 , C12P21/04 , C12N5/18 , C12N5/10 , A61P35/00 , C12N1/19 , C12N15/63 , C07K16/18 , C07H21/04 , A01K67/033 , A61K51/00 , C12N1/21
CPC分类号： C07K16/30 , A61K2039/5152 , A61K2039/545 , A61K2039/555 , C07K2317/73
摘要： The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.
摘要翻译： 本发明涉及使用来自对至少一种抗肿瘤化合物具有抗性的肿瘤的研磨的匀浆和/或悬浮液和/或细胞裂解物，以免疫和体外产生抗体，或其中之一 其功能片段，针对在所述抗性肿瘤表面特异性表达的肿瘤抗原，并可能参与所述抗性肿瘤的抗性。 更具体地，本发明涉及通过应用抗体1A6,1A9,2E11,3C11和3G7的方法获得的这些抗体以及它们用于治疗癌症的用途。
-
3.发明授权Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses 有权用于产生针对抗原抗原的活性抗体的方法，通过所述方法获得的抗体及其用途公开(公告)号：US08241646B2
公开(公告)日：2012-08-14
申请号：US12442918
申请日：2007-09-27
IPC分类号： A61K39/395 , A61K35/12
CPC分类号： C07K16/30 , A61K2039/5152 , A61K2039/545 , A61K2039/555 , C07K2317/73
摘要： The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.
摘要翻译： 本发明涉及使用来自对至少一种抗肿瘤化合物具有抗性的肿瘤的研磨的匀浆和/或悬浮液和/或细胞裂解物，以免疫和体外产生抗体，或其中之一 其功能片段，针对在所述抗性肿瘤表面特异性表达的肿瘤抗原，并可能参与所述抗性肿瘤的抗性。 更具体地，本发明涉及通过应用抗体1A6,1A9,2E11,3C11和3G7的方法获得的这些抗体以及它们用于治疗癌症的用途。
-
4.发明申请公开(公告)号：US20120149031A1
公开(公告)日：2012-06-14
申请号：US13391435
申请日：2010-08-23
CPC分类号： G01N33/57496 , C07K16/2863 , C07K2317/56 , C07K2317/565
摘要： The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to antibodies capable of binding to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding processes, for detecting and diagnosing pathological hyperproliterative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the overexpression of cMet. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers.
摘要翻译： 本发明涉及患者中增殖性疾病的预后和/或诊断领域。 更具体地，本发明涉及能够结合人cMet受体的抗体以及编码这些抗体的氨基酸和核酸序列。 本发明同样包括使用所述抗体和相应的方法来检测和诊断与cMet的表达相关的病理性过度压抑性致癌性疾病。 在某些实施方案中，所述疾病是与cMet多肽相对于正常或与cMet的过表达相关的任何其它病理学增加的表达增加相关的致癌性疾病。 本发明最终包括产品和/或组合物或试剂盒，其至少包含用于某些癌症的预后或诊断的抗体。
-
5.发明授权Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses 有权用于产生针对抗原抗原的活性抗体的方法，通过所述方法获得的抗体及其用途公开(公告)号：US08808667B2
公开(公告)日：2014-08-19
申请号：US13544672
申请日：2012-07-09
IPC分类号： A61K35/12 , A61K39/395 , A61K49/00 , G01N33/574 , C07K16/30
CPC分类号： C07K16/30 , A61K2039/5152 , A61K2039/545 , A61K2039/555 , C07K2317/73
摘要： The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.
摘要翻译： 本发明涉及使用来自对至少一种抗肿瘤化合物具有抗性的肿瘤的研磨的匀浆和/或悬浮液和/或细胞裂解物，以免疫和体外产生抗体，或其中之一 其功能片段，针对在所述抗性肿瘤表面特异性表达的肿瘤抗原，并可能参与所述抗性肿瘤的抗性。 更具体地，本发明涉及通过应用抗体1A6,1A9,2E11,3C11和3G7的方法获得的这些抗体以及它们用于治疗癌症的用途。
-
6.发明申请METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST A RESISTANCE ANTIGEN, ANTIBODIES OBTAINED BY SAID METHOD AND THEIR USES 有权用于产生抗性抗原的活性抗体的方法，通过方法获得的抗体及其用途公开(公告)号：US20100146650A1
公开(公告)日：2010-06-10
申请号：US12442918
申请日：2007-09-27
IPC分类号： A61K39/395 , C07K16/46 , C07H21/04 , C07H21/02 , A61K51/00 , A61P35/00 , C07K16/30 , C12P21/00 , C12N5/12 , C12N15/63 , C12N5/10 , A01K67/027
CPC分类号： C07K16/30 , A61K2039/5152 , A61K2039/545 , A61K2039/555 , C07K2317/73
摘要： The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.
摘要翻译： 本发明涉及使用来自对至少一种抗肿瘤化合物具有抗性的肿瘤的研磨的匀浆和/或悬浮液和/或细胞裂解物，以免疫和体外产生抗体，或其中之一 其功能片段，针对在所述抗性肿瘤表面特异性表达的肿瘤抗原，并可能参与所述抗性肿瘤的抗性。 更具体地，本发明涉及通过应用抗体1A6,1A9,2E11,3C11和3G7的方法获得的这些抗体以及它们用于治疗癌症的用途。
-
7.发明授权公开(公告)号：US09518120B2
公开(公告)日：2016-12-13
申请号：US14235274
申请日：2012-07-30
IPC分类号： C07K16/28 , G01N33/574
CPC分类号： G01N33/5748 , C07K16/2866 , C07K16/2896 , C07K2317/30 , C07K2317/51 , C07K2317/515 , C07K2317/565 , G01N33/574 , G01N2333/7158
摘要： The present invention provides a novel, isolated anti-CXCR4 antibody for use in the diagnosis of cancer. In particular, the antibody of the invention recognizes monomeric and homodimeric CXCR4, but not heterodimeric CXCR4.
摘要翻译： 本发明提供了用于诊断癌症的新型分离的抗CXCR4抗体。 特别地，本发明的抗体识别单体和同二聚CXCR4，但不识别异二聚CXCR4。
-
公开(公告)号：US09249223B2
公开(公告)日：2016-02-02
申请号：US13637198
申请日：2011-03-30
IPC分类号： C07K16/00 , A61K39/395 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/76
摘要： The present invention relates to a novel isolated humanized antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to hz515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered.
摘要翻译： 本发明涉及新型分离的人源化抗体，或其衍生化合物或其功能片段，其能够结合CXCR4，但也涉及诱导CXCR4同型二聚体和/或异二聚体的构象改变。 更具体地，本发明涉及对CXCR4蛋白特异的hz515H7抗体以及它们用于治疗癌症的用途。 还包括由这些抗体组成的药物组合物和选择这些抗体的方法。
-
9.发明申请公开(公告)号：US20140170677A1
公开(公告)日：2014-06-19
申请号：US14235235
申请日：2012-07-30
IPC分类号： G01N33/574 , C07K16/28
CPC分类号： G01N33/574 , A61K2039/505 , C07K16/2866 , C07K2317/565
摘要： The present invention relates to the use of a novel, isolated anti-CXCR4 antibody in the diagnosis of cancer. In particular, methods for diagnosing and/or prognosing an oncogenic disorder associated with CXCR4 expression, are disclosed.
摘要翻译： 本发明涉及新型分离的抗CXCR4抗体在癌症诊断中的应用。 特别地，公开了用于诊断和/或预测与CXCR4表达相关的致癌性疾病的方法。
-
公开(公告)号：US09120852B2
公开(公告)日：2015-09-01
申请号：US13807593
申请日：2011-06-29
IPC分类号： A61K39/395 , C07K16/28 , G01N33/574 , G01N33/68
CPC分类号： C07K16/2863 , C07K2317/32 , C07K2317/56 , C07K2317/565 , G01N33/57438 , G01N33/6872
摘要： The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to novel antibodies capable of binding specifically to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding process, for detecting and diagnosing pathological hyperproliferative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the over expression of c Met. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers.
摘要翻译： 本发明涉及患者中增殖性疾病的预后和/或诊断领域。 更具体地，本发明涉及能够特异性结合人cMet受体的新型抗体以及编码这些抗体的氨基酸和核酸序列。 本发明同样包括使用所述抗体和相应的方法来检测和诊断与cMet表达相关的病理性过度增生性致癌性疾病。 在某些实施方案中，所述疾病是与cMet多肽相对于正常或与c Met的过表达相关的任何其它病理学增加的表达相关的致癌疾病。 本发明最终包括产品和/或组合物或试剂盒，其至少包含用于某些癌症的预后或诊断的抗体。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.022 秒)
